These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 19560877)

  • 1. Is it the time for metformin to take place in adjuvant treatment of Her-2 positive breast cancer? Teaching new tricks to old dogs.
    Yurekli BS; Karaca B; Cetinkalp S; Uslu R
    Med Hypotheses; 2009 Oct; 73(4):606-7. PubMed ID: 19560877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy.
    Guarneri V; Conte P
    Oncologist; 2009 Jul; 14(7):645-56. PubMed ID: 19608638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting AMPK: a new therapeutic opportunity in breast cancer.
    Hadad SM; Fleming S; Thompson AM
    Crit Rev Oncol Hematol; 2008 Jul; 67(1):1-7. PubMed ID: 18343152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target-based therapies in breast cancer: current status and future perspectives.
    Normanno N; Morabito A; De Luca A; Piccirillo MC; Gallo M; Maiello MR; Perrone F
    Endocr Relat Cancer; 2009 Sep; 16(3):675-702. PubMed ID: 19525314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. If mammalian target of metformin indirectly is mammalian target of rapamycin, then the insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in cancer clinical trials.
    Vazquez-Martin A; Oliveras-Ferraros C; Del Barco S; Martin-Castillo B; Menendez JA
    J Clin Oncol; 2009 Nov; 27(33):e207-9; author reply e210. PubMed ID: 19858375
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effect of previous diabetes therapy on tumor receptor phenotype in breast cancer: comparison of metformin and sulphonylurea derivatives].
    Bershteĭn LM; Boriakina MP; Turkevich EA; Tsyrlina EV; Semiglazov VF
    Vopr Onkol; 2010; 56(3):312-6. PubMed ID: 20804053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin in breast cancer: time for action.
    Goodwin PJ; Ligibel JA; Stambolic V
    J Clin Oncol; 2009 Jul; 27(20):3271-3. PubMed ID: 19487373
    [No Abstract]   [Full Text] [Related]  

  • 8. Molecular biology of breast cancer stem cells: potential clinical applications.
    Nguyen NP; Almeida FS; Chi A; Nguyen LM; Cohen D; Karlsson U; Vinh-Hung V
    Cancer Treat Rev; 2010 Oct; 36(6):485-91. PubMed ID: 20231058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin in the adjuvant breast cancer setting: a novel therapeutic target for lifestyle and pharmacologic interventions?
    Goodwin PJ
    J Clin Oncol; 2008 Feb; 26(6):833-4. PubMed ID: 18281653
    [No Abstract]   [Full Text] [Related]  

  • 10. Obesity and insulin resistance in breast cancer--chemoprevention strategies with a focus on metformin.
    Goodwin PJ; Stambolic V
    Breast; 2011 Oct; 20 Suppl 3():S31-5. PubMed ID: 22015290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin as an addition to conventional chemotherapy in breast cancer.
    Grenader T; Goldberg A; Shavit L
    J Clin Oncol; 2009 Dec; 27(35):e259; author reply e260. PubMed ID: 19884518
    [No Abstract]   [Full Text] [Related]  

  • 12. Is it time to test metformin in breast cancer clinical trials?
    Cazzaniga M; Bonanni B; Guerrieri-Gonzaga A; Decensi A
    Cancer Epidemiol Biomarkers Prev; 2009 Mar; 18(3):701-5. PubMed ID: 19240238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of HER-2/neu receptor positivity and its association with other features of breast cancer.
    Naeem M; Nasir A; Aman Z; Ahmad T; Samad A
    J Ayub Med Coll Abbottabad; 2008; 20(3):23-6. PubMed ID: 19610508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacotherapy of triple-negative breast cancer.
    Arslan C; Dizdar O; Altundag K
    Expert Opin Pharmacother; 2009 Sep; 10(13):2081-93. PubMed ID: 19640211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of glucose-6-phosphatase gene expression by insulin and metformin.
    Mues C; Zhou J; Manolopoulos KN; Korsten P; Schmoll D; Klotz LO; Bornstein SR; Klein HH; Barthel A
    Horm Metab Res; 2009 Oct; 41(10):730-5. PubMed ID: 19579180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Teaching an old drug new tricks: metformin as a targeted therapy for lung cancer.
    Antonoff MB; D'Cunha J
    Semin Thorac Cardiovasc Surg; 2010; 22(3):195-6. PubMed ID: 21167452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant endocrine therapy in post menopausal women: pharmacological evaluation using decision analysis approach in a Japanese hospital setting.
    Miyazaki Y; Arakawa I; Inoue T
    Gan To Kagaku Ryoho; 2009 Aug; 36(8):1299-309. PubMed ID: 19692769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
    Hoeflich KP; O'Brien C; Boyd Z; Cavet G; Guerrero S; Jung K; Januario T; Savage H; Punnoose E; Truong T; Zhou W; Berry L; Murray L; Amler L; Belvin M; Friedman LS; Lackner MR
    Clin Cancer Res; 2009 Jul; 15(14):4649-64. PubMed ID: 19567590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential for targeting the fibroblast growth factor receptors in breast cancer.
    Hynes NE; Dey JH
    Cancer Res; 2010 Jul; 70(13):5199-202. PubMed ID: 20570901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome.
    Flowers A; Chu QD; Panu L; Meschonat C; Caldito G; Lowery-Nordberg M; Li BD
    Surgery; 2009 Aug; 146(2):220-6. PubMed ID: 19628077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.